Skip to main content
NOVELIX PHARMACEUTICALS LIMITED logo

NOVELIX PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 536565 ISIN · INE314I01036 LEI · 8945002HROSD4VUIYY08 BSE.NS Manufacturing
Open in API
Filings indexed 19 across all filing types
Latest filing 2026-05-29 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS 536565

About NOVELIX PHARMACEUTICALS LIMITED

https://novelixpharma.com/

Novelix Pharmaceuticals Limited specializes in the research, development, and large-scale manufacturing of pharmaceutical formulations and active ingredients. The company’s portfolio encompasses a broad spectrum of therapeutic segments, including cardiology, gastroenterology, and metabolic health. It focuses on the production of high-quality generic medications, utilizing sophisticated chemical synthesis and formulation technologies to ensure bioequivalence and safety. Core competencies include the development of diverse dosage forms such as oral solids, liquids, and parenteral preparations. By integrating rigorous quality management systems and advanced analytical testing, the organization maintains a commitment to delivering standardized healthcare solutions aimed at improving clinical outcomes across various medical disciplines.

Recent filings

Filing Released Lang Actions
Submission of Audited financial Results for the quarter and year ended 31st March, 2026.
Interim / Quarterly Report Classification · 94% confidence The document is an audited standalone financial results announcement submitted under Regulation 33 of SEBI LODR, containing detailed quarter-end and year-to-date financial statements (P&L, EPS, auditor’s report). It is not a full annual report (10-K) nor a mere earnings release (ER) with highlights only. Instead, it provides substantive financial data for a period shorter than a full fiscal year, matching our definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-29 English
Submission of Board Meeting outcome.
Regulatory Filings Classification · 85% confidence The document is an ‘Outcome of Board Meeting’ filed under Regulation 30 of SEBI LODR. It discloses approval of audited financial results, auditor re-appointment and share allotment details. It is a general regulatory announcement rather than the full annual/quarterly report itself, a financing memo alone, or a voting or board composition change. Therefore it falls under “Regulatory Filings” (RNS).
2026-05-29 English
Declaration of Non Applicability of Annual Secretarial Compliance Report.
Regulatory Filings Classification · 85% confidence The document is a letter from the company to the stock exchange declaring the non-applicability of the Annual Secretarial Compliance Report under SEBI Listing Regulations. It is an attestation/confirmation by an officer rather than the actual compliance report itself and primarily serves as a regulatory announcement. Under the certification rule, such officer confirmations belong in Regulatory Filings (RNS), not as the report itself.
2026-05-27 English
Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Issue of equity shares ....
Regulatory Filings Classification · 85% confidence The document is a formal intimation to the stock exchange (BSE) under SEBI LODR Regulation 29 about a forthcoming Board meeting to approve financial results and other corporate matters. It does not contain the actual results or minutes but is a compliance/regulatory announcement. This falls under the general regulatory filings category.
2026-05-25 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.